Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02485769
Previous Study | Return to List | Next Study

Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Oral Pf-06650833 In Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02485769
Recruitment Status : Completed
First Posted : June 30, 2015
Last Update Posted : April 19, 2018
Sponsor:
Information provided by (Responsible Party):
Pfizer

Tracking Information
First Submitted Date  ICMJE May 28, 2015
First Posted Date  ICMJE June 30, 2015
Last Update Posted Date April 19, 2018
Actual Study Start Date  ICMJE June 2015
Actual Primary Completion Date April 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 25, 2015)
  • Incidence and severity of treatment emergent adverse events. [ Time Frame: 50 days ]
  • Incidence and Magnitude of Participants with Treatment-emergent hematology clinical abnormalities [ Time Frame: 50 days ]
  • Incidence and Magnitude of Participants with Treatment-emergent chemistry abnormalities (including, cardiac enzymes CK, CK-MB and cardiac Troponin-1, serum myoglobin) [ Time Frame: 50 days ]
  • Incidence and Magnitude of Participants with Treatment-emergent urinalysis abnormalities [ Time Frame: 50 Days ]
  • Changes from baseline in blood pressure [ Time Frame: 50 days ]
  • Changes from baseline in pulse rate [ Time Frame: 50 days ]
  • Changes from baseline in respiratory rate [ Time Frame: 50 days ]
  • Changes from baseline in ECG parameters (standard 12-lead ECG) [ Time Frame: 50 days ]
  • Changes from baseline in Epstein-Barr virus [EBV] [ Time Frame: 50 days ]
  • Changes from baseline in Cytomegalovirus [CMV] [ Time Frame: 50 days ]
  • Changes from baseline in Herpes simplex virus-1 and -2 [HSV-1 and HSV-2] [ Time Frame: 50 days ]
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT02485769 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: June 25, 2015)
  • To characterize Cmax in plasma [ Time Frame: Day 1 and Day 14 ]
  • To determine PF-06650833 excreted unchanged (AE tau and AE tau %), [ Time Frame: Day 14 ]
  • To characterize Tmax in plasma [ Time Frame: Day 1 and Day 14 ]
  • To characterize AUC tau in plasma [ Time Frame: Day 1 and Day 14 ]
  • To characterize Cmin in plasma [ Time Frame: Day 1 and Day 14 ]
  • Characterize Cmax (dose normalized) in plasma [ Time Frame: Day 1 and Day 14 ]
  • To characterize AUC tau(dose normalized) in plasma [ Time Frame: day1 and day 14 ]
  • To determine the renal clearance (CLr) [ Time Frame: Day 14 ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Oral Pf-06650833 In Healthy Subjects
Official Title  ICMJE A Phase 1, Randomized, Double Blind, Sponsor Open, Placebo Controlled, Sequential Group, Multiple Ascending Dose Escalation Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Orally Administered Pf 06650833 In Healthy Subjects
Brief Summary A Phase 1, Randomized, Double Blind, Sponsor Open, Placebo Controlled, Sequential Group, Multiple Ascending Dose Escalation Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Orally Administered PF-06650833 In Healthy Subjects
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Healthy
Intervention  ICMJE
  • Drug: PF-06650833
    Suspension
  • Drug: Placebo
    Suspension
  • Drug: PF-06650833
    Tablet (Modified Release)
  • Drug: Placebo
    Tablet (Modified Release)
Study Arms  ICMJE
  • Experimental: PF-06650833
    Active arm , PF-06650833 kinase.
    Interventions:
    • Drug: PF-06650833
    • Drug: PF-06650833
  • Placebo Comparator: Placebo
    Placebo arm
    Interventions:
    • Drug: Placebo
    • Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 6, 2016)
71
Original Estimated Enrollment  ICMJE
 (submitted: June 25, 2015)
50
Actual Study Completion Date  ICMJE April 2016
Actual Primary Completion Date April 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Healthy female subjects of non childbearing potential and/or male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive.
  2. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
  3. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
  4. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

  1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  2. Any condition possibly affecting drug absorption (eg, gastrectomy).
  3. A positive urine drug screen.
  4. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of Screening.
  5. Smokers must not exceed the equivalent of 5 cigarettes per day.
  6. Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of investigational product (whichever is longer).
  7. Screening supine blood pressure100 mm Hg (systolic) or 50 mm Hg (diastolic); or 140 mm Hg (systolic) or 90 mm Hg (diastolic) following at least 5 minutes of supine rest. If blood pressure (BP) is 40 mm Hg (systolic) or 90 mm Hg (diastolic), the BP should be repeated two more times and the average of the three BP values should be used to determine the subject's eligibility.
  8. Screening pulse or heart rate (HR) >100 bpm after at least 5 minutes of rest. If the pulse/HR is >100 bpm, the pulse/HR should be repeated two more times (separated by at least 2 minutes) and the average of the three pulse/HR values should be used to determine the subject's eligibility.
  9. Screening 12 lead ECG demonstrating QTc >450 msec or a QRS interval >120 msec. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTc or QRS values should be used to determine the subject's eligibility.
  10. Clinically significant abnormality on chest X ray performed at screening or within 3 months of screening date.
  11. History of tuberculosis or active or latent or inadequately treated infection, positive Quantiferon TB test
  12. History of hepatitis or HIV, positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HepBsAg), hepatitis B core antibodies (HepBcAb) or hepatitis C antibodies (HCVAb).
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02485769
Other Study ID Numbers  ICMJE B7921002
IRAK4 MAD ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Pfizer CT.gov Call Center Pfizer
PRS Account Pfizer
Verification Date April 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP